Skip to main content

Free Content Review of the Indian market of anti-tuberculosis drugs: focus on the utilisation of rifampicin-based products

Download Article:
(PDF 552.427734375 kb)


SETTING: There is a need to better understand the extent of the utilisation of rifampicin in the market, particularly in fixed-dose combinations (FDC).

OBJECTIVE: To review the Indian market of anti-tuberculosis drugs, as this is the largest single market in the world of this therapeutic class.

DESIGN: Review and analysis of the sales data proffered by the Indian market audit. Estimated data relating to public sector product usage were utilised in order to obtain a more complete scenario.

RESULTS: The use of rifampicin-based products is very important in the Indian market of anti-tuberculosis drugs. Particularly common is the use of FDCs, which represent 62% of anti-tuberculosis drugs sold in the private market.

CONCLUSIONS: The Indian market for anti-tuberculosis drugs is very large and well integrated. FDCs are widely used. In addition to double- and triple-drug FDCs, four-drug combinations have recently been introduced into the market. The Indian industry also exports raw materials and pharmaceutical specialities.

Keywords: dosage ratios; fixed-dose combinations; market; rifampicin

Document Type: Review Article

Affiliations: Hoechst Marion Roussel, Milan, Italy

Publication date: 1999-11-01

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more